Preliminary data from a phase I trial of the pan-KRAS inhibitor RMC-6236 in patients with previously treated mPDAC (n  =  22) and non-small-cell lung cancer (NSCLC) (n  =  11) harboring different KRAS mutations excluding G12C (NCT05379985), showed an overall response rate of 36% and a disease control rate of 86% [29]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.